Pulmonary Emphysema Market - A Global and Regional Analysis: Focus on Country, and Regional Analysis - Analysis and Forecast, 2025-2035
Description
Market Overview
The global pulmonary emphysema market is driven by the increasing prevalence of chronic obstructive pulmonary disease (COPD), of which emphysema is a significant form. Smoking, environmental pollutants, and an aging population contribute to the rising incidence of emphysema worldwide. Treatment options, including bronchodilators, inhaled corticosteroids, and combination therapies, remain the foundation for symptom management and disease control. The approval of novel biologic therapies targeting inflammation, such as Dupixent (dupilumab), is expected to drive market growth. The market faces challenges such as high treatment costs and the need for improved patient adherence. However, advancements in therapeutic options provide significant opportunities for market expansion.
Impact
Increasing demand for pulmonary emphysema therapies is anticipated to support the growth of the global pulmonary emphysema market during the forecast period 2025-2035.
The global pulmonary emphysema market is expected to grow at a significant rate due to advancements in treatment, the development of innovative therapies, and increasing awareness among patients and healthcare providers.
Demand – Drivers and Limitations
The following are the drivers for the global pulmonary emphysema market:
Increased Prevalence of Chronic Obstructive Pulmonary Disease (COPD): The rise in smoking, air pollution, and aging populations globally contributes to the growing number of pulmonary emphysema cases, expanding the target patient base for treatment.
Advancements in Targeted Therapies: The introduction of biologic treatments targeting interleukins for inflammation control is driving growth in more severe disease stages, improving patient outcomes.
Combination Therapy Development: The continuous evolution of combination therapies has improved patient convenience and adherence, making it easier to manage symptoms and reduce exacerbations.
The global pulmonary emphysema market is expected to face some limitations too, due to the following challenges:
High Treatment Costs: The cost of biologic treatments and combination inhalers remains high, limiting access in low- and middle-income countries, affecting market penetration.
How Can This Report Add Value to an Organization?
Product/Innovation Strategy: This report provides insights into emerging therapies, such as biologic treatments and novel combination therapies, helping organizations align their R&D with the evolving market needs. It also highlights regulatory trends and patient management practices, guiding innovation to address disease progression and adherence issues.
Competitive Strategy: The report outlines the competitive landscape, focusing on market leaders like GSK plc and AstraZeneca. It offers actionable insights into market share dynamics, pricing strategies, and clinical differentiation, enabling organizations to identify opportunities for collaboration, licensing, and regional market expansion.
Key Market Players and Competition Synopsis
Key players in the global pulmonary emphysema market include GSK plc, Novartis AG, Boehringer Ingelheim Pharmaceuticals, Inc. , AstraZeneca, and Sanofi. Leading products such as Spiriva (tiotropium), Competitive strategies focus on the development of combination therapies, with an emphasis on improving patient adherence and long-term efficacy. Companies are also focusing on improving drug delivery systems and expanding global access, particularly in emerging markets where the prevalence of COPD and emphysema is increasing.
Some of the prominent names established in this market are:
AstraZeneca
Sanofi
Boehringer Ingelheim Pharmaceuticals, Inc.
GSK plc
Novartis AG
*PDF email from publisher allows for 1-3 users, with permission to print*
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
The global pulmonary emphysema market is driven by the increasing prevalence of chronic obstructive pulmonary disease (COPD), of which emphysema is a significant form. Smoking, environmental pollutants, and an aging population contribute to the rising incidence of emphysema worldwide. Treatment options, including bronchodilators, inhaled corticosteroids, and combination therapies, remain the foundation for symptom management and disease control. The approval of novel biologic therapies targeting inflammation, such as Dupixent (dupilumab), is expected to drive market growth. The market faces challenges such as high treatment costs and the need for improved patient adherence. However, advancements in therapeutic options provide significant opportunities for market expansion.
Impact
Increasing demand for pulmonary emphysema therapies is anticipated to support the growth of the global pulmonary emphysema market during the forecast period 2025-2035.
The global pulmonary emphysema market is expected to grow at a significant rate due to advancements in treatment, the development of innovative therapies, and increasing awareness among patients and healthcare providers.
Demand – Drivers and Limitations
The following are the drivers for the global pulmonary emphysema market:
Increased Prevalence of Chronic Obstructive Pulmonary Disease (COPD): The rise in smoking, air pollution, and aging populations globally contributes to the growing number of pulmonary emphysema cases, expanding the target patient base for treatment.
Advancements in Targeted Therapies: The introduction of biologic treatments targeting interleukins for inflammation control is driving growth in more severe disease stages, improving patient outcomes.
Combination Therapy Development: The continuous evolution of combination therapies has improved patient convenience and adherence, making it easier to manage symptoms and reduce exacerbations.
The global pulmonary emphysema market is expected to face some limitations too, due to the following challenges:
High Treatment Costs: The cost of biologic treatments and combination inhalers remains high, limiting access in low- and middle-income countries, affecting market penetration.
How Can This Report Add Value to an Organization?
Product/Innovation Strategy: This report provides insights into emerging therapies, such as biologic treatments and novel combination therapies, helping organizations align their R&D with the evolving market needs. It also highlights regulatory trends and patient management practices, guiding innovation to address disease progression and adherence issues.
Competitive Strategy: The report outlines the competitive landscape, focusing on market leaders like GSK plc and AstraZeneca. It offers actionable insights into market share dynamics, pricing strategies, and clinical differentiation, enabling organizations to identify opportunities for collaboration, licensing, and regional market expansion.
Key Market Players and Competition Synopsis
Key players in the global pulmonary emphysema market include GSK plc, Novartis AG, Boehringer Ingelheim Pharmaceuticals, Inc. , AstraZeneca, and Sanofi. Leading products such as Spiriva (tiotropium), Competitive strategies focus on the development of combination therapies, with an emphasis on improving patient adherence and long-term efficacy. Companies are also focusing on improving drug delivery systems and expanding global access, particularly in emerging markets where the prevalence of COPD and emphysema is increasing.
Some of the prominent names established in this market are:
AstraZeneca
Sanofi
Boehringer Ingelheim Pharmaceuticals, Inc.
GSK plc
Novartis AG
*PDF email from publisher allows for 1-3 users, with permission to print*
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Table of Contents
- Executive Summary
- Scope of Study
- Research Methodology
- 1. Global Pulmonary Emphysema Market: Industry Outlook
- 1.1 Market Overview
- 1.2 Epidemiological Analysis
- 1.3 Clinical Trials
- 1.4 Regulatory Landscape / Compliance
- 1.5 Key Trends
- 1.6 Market Dynamics
- 1.6.1 Impact Analysis
- 1.6.2 Market Drivers
- 1.6.3 Market Restraints
- 1.6.4 Market Opportunities
- 2. Global Pulmonary Emphysema Market (By Region), $Million, 2024-2035
- 2.1 North America
- 2.1.1 Market Dynamics
- 2.1.2 Market Sizing and Forecast
- 2.1.2.1 North America Pulmonary Emphysema Market, by Country
- 2.1.2.1.1 U.S.
- 2.2 Europe
- 2.2.1 Market Dynamics
- 2.2.2 Market Sizing and Forecast
- 2.2.2.1 Europe Pulmonary Emphysema Market, by Country
- 2.2.2.1.1 U.K.
- 2.2.2.1.2 Germany
- 2.2.2.1.3 France
- 2.2.2.1.4 Italy
- 2.2.2.1.5 Spain
- 2.2.2.1.6 Rest-of-Europe
- 2.3 Asia-Pacific
- 2.3.1 Market Dynamics
- 2.3.2 Market Sizing and Forecast
- 2.3.2.1 Asia-Pacific Pulmonary Emphysema Market, by Country
- 2.3.2.1.1 Japan
- 2.3.2.1.2 Rest-of-Asia-Pacific
- 2.4 Rest-of-the-World
- 2.4.1 Market Dynamics
- 2.4.2 Market Sizing and Forecast
- 3. Global Pulmonary Emphysema Market - Competitive Landscape and Company Profiles
- 3.1 Key Developments and Strategies
- 3.1.1 Funding Activities
- 3.1.2 Mergers and Acquisitions
- 3.1.3 Regulatory Approvals
- 3.1.4 Partnerships, Collaborations and Business Expansions
- 3.2 Company Profiles
- 3.2.1 AstraZeneca
- 3.2.1.1 Company Overview
- 3.2.1.2 Product Portfolio
- 3.2.1.3 Target Customers/End Users
- 3.2.1.4 Analyst View
- 3.2.2 Sanofi
- 3.2.2.1 Company Overview
- 3.2.2.2 Product Portfolio
- 3.2.2.3 Target Customers/End Users
- 3.2.2.4 Analyst View
- 3.2.3 Boehringer Ingelheim Pharmaceuticals, Inc.
- 3.2.3.1 Company Overview
- 3.2.3.2 Product Portfolio
- 3.2.3.3 Target Customers/End Users
- 3.2.3.4 Analyst View
- 3.2.4 GSK plc
- 3.2.4.1 Company Overview
- 3.2.4.2 Product Portfolio
- 3.2.4.3 Target Customers/End Users
- 3.2.4.4 Analyst View
- 3.2.5 Novartis AG
- 3.2.5.1 Company Overview
- 3.2.5.2 Product Portfolio
- 3.2.5.3 Target Customers/End Users
- 3.2.5.4 Analyst View
- 3.2.6 Others
- 4. Research Methodology
- List of Figures
- Figure: Pulmonary Emphysema Market (by Scenario), $Million, 2024, 2030, and 2035
- Figure: Global Pulmonary Emphysema Market, 2024 and 2035
- Figure: Global Pulmonary Emphysema Market Key Trends, Impact Analysis, 2024-2035
- Figure: North America Pulmonary Emphysema Market, $Million, 2024-2035
- Figure: Europe Pulmonary Emphysema Market, $Million, 2024-2035
- Figure: Asia-Pacific Pulmonary Emphysema Market, $Million, 2024-2035
- Figure: Rest-of-the-World Pulmonary Emphysema Market, $Million, 2024-2035
- List of Tables
- Table: Market Snapshot
- Table: Market Dynamics
- Table: Global Pulmonary Emphysema Market (by Region), $Million, 2024-2035
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
